Please login to the form below

Not currently logged in

Nabriva Therapeutics adds Will Sargent to team

Join as VP of commercial strategy and investor relations
Will Sargent Nabriva Therapeutics

Nabriva Therapeutics has appointed Will Sargent in the newly created position of vice president of commercial strategy and investor relations.

Sargent has over twenty years of experience in the biopharmaceutical industry, including multiple product and line extension launches. His most recent position was as VP of the orthopaedic business unit at Auxilium Pharmaceuticals.

Nabriva is currently moving rapidly to advance its lead product, lefamulin, into phase III clinical studies which are expected to begin enrolling in 2015 and 2016.

He said: “I am excited to join this talented and dedicated team focused on advancing a novel, targeted antibiotic therapy that can impact patients' lives by addressing an unmet medical need.

“I look forward to applying my experience toward the successful development and implementation of the lefamulin commercial strategy and expansion of corporate communications.”

Dr Colin Broom, CEO of Nabriva, added: “Will's strategic focus, experience and breadth of knowledge will help us plan and execute toward our commercial path goals.”

14th October 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Haseeb Ahmad
Can value-based healthcare take off and reach for the skies?
Are companies willing to contribute to the change in the healthcare system?...
Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...